Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218153 · ClinicalTrials.gov registry record · Phase 3
Naltrexone Augmentation of Nicotine Patch Therapy - 1
A Phase 3 study of Tobacco Use Disorder, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT00218153 is a Phase 3 study of Tobacco Use Disorder that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 200 participants, below the 237-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (16% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00218153, a Phase 3 study of Tobacco Use Disorder, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
Naltrexone Augmentation of Nicotine Patch Therapy
Conditions Studied
Interventions
- DRUG Naltrexone
Study Locations (2)
Connecticut
- Substance Abuse Treatment Unit - New Haven
- VA Connecticut Health Care System - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2000-11 |
| Est. Completion | 2004-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00218153
The ClinicalTrials.gov registry entry for NCT00218153 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 237-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (16% lower). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Naltrexone is the first listed.
NCT00218153 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00218153 about?
NCT00218153 is a clinical study titled "Naltrexone Augmentation of Nicotine Patch Therapy - 1". Naltrexone Augmentation of Nicotine Patch Therapy
What is the current status of trial NCT00218153?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2000-11. Estimated completion is 2004-04.
What conditions does trial NCT00218153 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT00218153?
The interventions under investigation include: Naltrexone (DRUG).
Who is sponsoring clinical trial NCT00218153?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00218153 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cannabis-Tobacco Co-Use Treatment Study
RECRUITING · Phase 3
-
Non-Nicotine Agents for Smoking Cessation
COMPLETED · Phase 3
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
-
Smoking Cessation CM for Veterans With or at Risk for Cancer
RECRUITING · NA
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Cannabidiol for Reducing Cigarette Use
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.